On Friday, Mizuho Securities adjusted its outlook on shares of Intuitive Surgical (NASDAQ:ISRG), increasing the price target to $550 from the previous $500, while maintaining a Neutral stance on the stock.
The revision follows Intuitive Surgical's report of a $36 million and $0.20 earnings beat, driven by an 18% rise in procedure volumes and a significant increase in Da Vinci 5 (DV5) system placements, which saw 110 units placed in the third quarter compared to 70 in the second quarter.
The company experienced a year-over-year procedure growth rate of 17%, after adjusting for additional days, with international expansion fueled by general surgery, gynecology, and thoracic procedures. Despite a mid-single-digit decline in U.S. bariatric volumes, aligning with second-quarter trends due to ongoing GLP-1 challenges, the overall performance was robust.
Surgeons have reported early positive experiences with the DV5 system, noting improvements such as reduced surgery time and a quicker learning curve. The feedback highlights the force feedback and case insights solutions as critical factors in the system's adoption. However, supply constraints for the DV5 are still present, indicating that a full-scale launch is anticipated to occur next year.
Mizuho's updated position reflects these recent developments and anticipates a gradual progression for Intuitive Surgical. The firm has made slight adjustments to its estimates while reiterating its Neutral rating, indicating a cautious but acknowledging response to the company's current trajectory and potential for growth.
In other recent news, Intuitive Surgical has reported a robust third quarter for 2024, with significant growth in procedures and system placements. The company's revenue reached $2 billion, marking a 17% year-over-year increase, driven by an 18% rise in DaVinci procedures.
The installed base of DaVinci systems grew to approximately 9,300 multi-port systems globally, and 379 systems were placed in Q3. The company has also raised its full-year 2024 procedure growth forecast to a range of 16% to 17%.
Intuitive Surgical's latest DaVinci 5 system, launched in March 2024, has seen 188 installations and over 12,000 procedures completed. The Ion endoluminal system now has 736 installations and has been used in over 150,000 lung biopsies. Furthermore, the company's digital initiatives have expanded, with nearly 3,000 DaVinci virtual reality simulators installed.
Despite the positive developments, Intuitive Surgical faces ongoing pricing pressures in China due to value-based pricing adjustments and the introduction of domestic competitors. However, the company anticipates a broad launch of DaVinci 5 by mid-2025 and is focusing on expanding the Ion system internationally, particularly in China and Europe.
InvestingPro Insights
Intuitive Surgical's recent performance aligns with several InvestingPro metrics and tips. The company's market cap stands at an impressive $168.4 billion, reflecting its strong position in the medical technology sector. The revenue growth of 14.47% in Q2 2024 supports the 18% rise in procedure volumes mentioned in the article.
An InvestingPro Tip highlights that Intuitive Surgical is trading near its 52-week high, which is consistent with the stock's positive momentum following the earnings beat. The company's profitability is underscored by another tip indicating it has been profitable over the last twelve months, with a robust operating income margin of 25.79%.
However, investors should note that Intuitive Surgical is trading at a high P/E ratio of 80.27, suggesting the stock may be priced for high growth expectations. This valuation metric aligns with the InvestingPro Tip that the company is trading at a high earnings multiple.
For readers interested in a deeper analysis, InvestingPro offers 10 additional tips that could provide further insights into Intuitive Surgical's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.